nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—colon cancer—liver cancer	0.187	0.412	CtDrD
Methotrexate—stomach cancer—liver cancer	0.152	0.335	CtDrD
Methotrexate—MTHFR—liver cancer	0.142	0.75	CbGaD
Methotrexate—lung cancer—liver cancer	0.115	0.252	CtDrD
Methotrexate—ALB—liver cancer	0.0474	0.25	CbGaD
Methotrexate—ABCC10—Doxorubicin—liver cancer	0.0379	0.192	CbGbCtD
Methotrexate—ABCC4—Sorafenib—liver cancer	0.03	0.152	CbGbCtD
Methotrexate—ABCC1—Epirubicin—liver cancer	0.0275	0.139	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—liver cancer	0.0238	0.12	CbGbCtD
Methotrexate—ABCC2—Sorafenib—liver cancer	0.0178	0.0902	CbGbCtD
Methotrexate—ABCG2—Sorafenib—liver cancer	0.0161	0.0816	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—liver cancer	0.0146	0.0739	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—liver cancer	0.0108	0.0547	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—liver cancer	0.00979	0.0495	CbGbCtD
Methotrexate—ABCC2—bile canaliculus—liver cancer	0.00894	0.293	CbGeAlD
Methotrexate—ABCB1—Sorafenib—liver cancer	0.00582	0.0294	CbGbCtD
Methotrexate—ABCB1—Doxorubicin—liver cancer	0.00353	0.0178	CbGbCtD
Methotrexate—ABCC3—bile duct—liver cancer	0.0035	0.115	CbGeAlD
Methotrexate—ABCC2—bile duct—liver cancer	0.00279	0.0915	CbGeAlD
Methotrexate—ABCC2—bile—liver cancer	0.00215	0.0703	CbGeAlD
Methotrexate—ABCC11—embryo—liver cancer	0.00144	0.0472	CbGeAlD
Methotrexate—ATIC—embryo—liver cancer	0.00085	0.0278	CbGeAlD
Methotrexate—AOX1—gall bladder—liver cancer	0.000762	0.025	CbGeAlD
Methotrexate—ABCC3—gall bladder—liver cancer	0.000746	0.0244	CbGeAlD
Methotrexate—ABCC11—liver—liver cancer	0.000667	0.0218	CbGeAlD
Methotrexate—ALB—gall bladder—liver cancer	0.000636	0.0208	CbGeAlD
Methotrexate—SLC19A1—liver—liver cancer	0.00061	0.02	CbGeAlD
Methotrexate—DHFR—embryo—liver cancer	0.000571	0.0187	CbGeAlD
Methotrexate—SLC46A1—liver—liver cancer	0.00047	0.0154	CbGeAlD
Methotrexate—GGH—liver—liver cancer	0.000462	0.0151	CbGeAlD
Methotrexate—Folic Acid—MTHFR—liver cancer	0.000444	0.383	CrCbGaD
Methotrexate—Tetrahydrofolic acid—MTHFR—liver cancer	0.000444	0.383	CrCbGaD
Methotrexate—SLCO4C1—liver—liver cancer	0.00041	0.0134	CbGeAlD
Methotrexate—FPGS—liver—liver cancer	0.000406	0.0133	CbGeAlD
Methotrexate—SLCO1B3—liver—liver cancer	0.000398	0.0131	CbGeAlD
Methotrexate—ATIC—liver—liver cancer	0.000393	0.0129	CbGeAlD
Methotrexate—SLC22A11—liver—liver cancer	0.000317	0.0104	CbGeAlD
Methotrexate—SLC22A7—liver—liver cancer	0.00031	0.0101	CbGeAlD
Methotrexate—MTHFR—liver—liver cancer	0.000292	0.00957	CbGeAlD
Methotrexate—SLCO3A1—liver—liver cancer	0.000287	0.00942	CbGeAlD
Methotrexate—Folic Acid—CYP2E1—liver cancer	0.00027	0.233	CrCbGaD
Methotrexate—TYMS—liver—liver cancer	0.000267	0.00873	CbGeAlD
Methotrexate—DHFR—liver—liver cancer	0.000264	0.00865	CbGeAlD
Methotrexate—PGD—liver—liver cancer	0.000254	0.00831	CbGeAlD
Methotrexate—SLC16A1—liver—liver cancer	0.000237	0.00776	CbGeAlD
Methotrexate—SLCO1B1—liver—liver cancer	0.00023	0.00755	CbGeAlD
Methotrexate—AOX1—liver—liver cancer	0.000224	0.00732	CbGeAlD
Methotrexate—ABCC3—liver—liver cancer	0.000219	0.00716	CbGeAlD
Methotrexate—ABCC10—liver—liver cancer	0.000218	0.00713	CbGeAlD
Methotrexate—SLCO1A2—liver—liver cancer	0.000188	0.00614	CbGeAlD
Methotrexate—ALB—liver—liver cancer	0.000186	0.00611	CbGeAlD
Methotrexate—ABCC4—liver—liver cancer	0.00018	0.00591	CbGeAlD
Methotrexate—ABCC2—liver—liver cancer	0.000175	0.00572	CbGeAlD
Methotrexate—ABCC1—liver—liver cancer	0.000154	0.00504	CbGeAlD
Methotrexate—ABCB1—embryo—liver cancer	0.000136	0.00445	CbGeAlD
Methotrexate—ABCG2—liver—liver cancer	0.000127	0.00417	CbGeAlD
Methotrexate—Bladder pain—Epirubicin—liver cancer	0.000112	0.00165	CcSEcCtD
Methotrexate—Ecchymosis—Epirubicin—liver cancer	0.000112	0.00165	CcSEcCtD
Methotrexate—Neoplasm—Epirubicin—liver cancer	0.000112	0.00165	CcSEcCtD
Methotrexate—Mouth ulceration—Epirubicin—liver cancer	0.000112	0.00165	CcSEcCtD
Methotrexate—Cystitis noninfective—Doxorubicin—liver cancer	0.000112	0.00165	CcSEcCtD
Methotrexate—Melaena—Doxorubicin—liver cancer	0.000112	0.00165	CcSEcCtD
Methotrexate—Cystitis—Doxorubicin—liver cancer	0.000111	0.00163	CcSEcCtD
Methotrexate—Pulmonary oedema—Epirubicin—liver cancer	0.00011	0.00163	CcSEcCtD
Methotrexate—Skin exfoliation—Doxorubicin—liver cancer	0.00011	0.00161	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000109	0.00161	CcSEcCtD
Methotrexate—Vaginal infection—Doxorubicin—liver cancer	0.000108	0.0016	CcSEcCtD
Methotrexate—Aplastic anaemia—Doxorubicin—liver cancer	0.000108	0.00159	CcSEcCtD
Methotrexate—Sepsis—Epirubicin—liver cancer	0.000108	0.00159	CcSEcCtD
Methotrexate—Dyspnoea—Sorafenib—liver cancer	0.000107	0.00157	CcSEcCtD
Methotrexate—Lymphadenopathy—Epirubicin—liver cancer	0.000106	0.00156	CcSEcCtD
Methotrexate—Dyspepsia—Sorafenib—liver cancer	0.000105	0.00155	CcSEcCtD
Methotrexate—Coma—Doxorubicin—liver cancer	0.000105	0.00155	CcSEcCtD
Methotrexate—Decreased appetite—Sorafenib—liver cancer	0.000104	0.00153	CcSEcCtD
Methotrexate—Thrombophlebitis—Epirubicin—liver cancer	0.000104	0.00153	CcSEcCtD
Methotrexate—Ecchymosis—Doxorubicin—liver cancer	0.000104	0.00153	CcSEcCtD
Methotrexate—Neoplasm—Doxorubicin—liver cancer	0.000104	0.00153	CcSEcCtD
Methotrexate—Bladder pain—Doxorubicin—liver cancer	0.000104	0.00153	CcSEcCtD
Methotrexate—Mouth ulceration—Doxorubicin—liver cancer	0.000104	0.00153	CcSEcCtD
Methotrexate—Diabetes mellitus—Epirubicin—liver cancer	0.000104	0.00153	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Sorafenib—liver cancer	0.000103	0.00152	CcSEcCtD
Methotrexate—Fatigue—Sorafenib—liver cancer	0.000103	0.00152	CcSEcCtD
Methotrexate—Photosensitivity—Epirubicin—liver cancer	0.000103	0.00151	CcSEcCtD
Methotrexate—Pain—Sorafenib—liver cancer	0.000102	0.00151	CcSEcCtD
Methotrexate—Pulmonary oedema—Doxorubicin—liver cancer	0.000102	0.00151	CcSEcCtD
Methotrexate—Hepatic failure—Epirubicin—liver cancer	0.0001	0.00148	CcSEcCtD
Methotrexate—Sepsis—Doxorubicin—liver cancer	9.97e-05	0.00147	CcSEcCtD
Methotrexate—Gastrointestinal pain—Sorafenib—liver cancer	9.8e-05	0.00144	CcSEcCtD
Methotrexate—Lymphadenopathy—Doxorubicin—liver cancer	9.77e-05	0.00144	CcSEcCtD
Methotrexate—Renal failure acute—Epirubicin—liver cancer	9.76e-05	0.00144	CcSEcCtD
Methotrexate—Thrombophlebitis—Doxorubicin—liver cancer	9.63e-05	0.00142	CcSEcCtD
Methotrexate—Diabetes mellitus—Doxorubicin—liver cancer	9.58e-05	0.00141	CcSEcCtD
Methotrexate—Dermatitis exfoliative—Epirubicin—liver cancer	9.55e-05	0.00141	CcSEcCtD
Methotrexate—Urticaria—Sorafenib—liver cancer	9.52e-05	0.0014	CcSEcCtD
Methotrexate—Photosensitivity—Doxorubicin—liver cancer	9.49e-05	0.0014	CcSEcCtD
Methotrexate—Body temperature increased—Sorafenib—liver cancer	9.47e-05	0.0014	CcSEcCtD
Methotrexate—Abdominal pain—Sorafenib—liver cancer	9.47e-05	0.0014	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Epirubicin—liver cancer	9.31e-05	0.00137	CcSEcCtD
Methotrexate—Hepatic failure—Doxorubicin—liver cancer	9.28e-05	0.00137	CcSEcCtD
Methotrexate—Lethargy—Epirubicin—liver cancer	9.19e-05	0.00135	CcSEcCtD
Methotrexate—Cerebrovascular accident—Epirubicin—liver cancer	9.19e-05	0.00135	CcSEcCtD
Methotrexate—Renal failure acute—Doxorubicin—liver cancer	9.03e-05	0.00133	CcSEcCtD
Methotrexate—Osteoarthritis—Epirubicin—liver cancer	9.01e-05	0.00133	CcSEcCtD
Methotrexate—Dermatitis exfoliative—Doxorubicin—liver cancer	8.83e-05	0.0013	CcSEcCtD
Methotrexate—Hypersensitivity—Sorafenib—liver cancer	8.83e-05	0.0013	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Doxorubicin—liver cancer	8.61e-05	0.00127	CcSEcCtD
Methotrexate—Asthenia—Sorafenib—liver cancer	8.6e-05	0.00127	CcSEcCtD
Methotrexate—Mood swings—Epirubicin—liver cancer	8.53e-05	0.00126	CcSEcCtD
Methotrexate—Cerebrovascular accident—Doxorubicin—liver cancer	8.51e-05	0.00125	CcSEcCtD
Methotrexate—Lethargy—Doxorubicin—liver cancer	8.51e-05	0.00125	CcSEcCtD
Methotrexate—Pruritus—Sorafenib—liver cancer	8.48e-05	0.00125	CcSEcCtD
Methotrexate—Ataxia—Epirubicin—liver cancer	8.47e-05	0.00125	CcSEcCtD
Methotrexate—Osteoarthritis—Doxorubicin—liver cancer	8.34e-05	0.00123	CcSEcCtD
Methotrexate—Liver function test abnormal—Epirubicin—liver cancer	8.32e-05	0.00123	CcSEcCtD
Methotrexate—Diarrhoea—Sorafenib—liver cancer	8.2e-05	0.00121	CcSEcCtD
Methotrexate—Breast disorder—Epirubicin—liver cancer	8.14e-05	0.0012	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Epirubicin—liver cancer	8.11e-05	0.00119	CcSEcCtD
Methotrexate—Dizziness—Sorafenib—liver cancer	7.92e-05	0.00117	CcSEcCtD
Methotrexate—Mood swings—Doxorubicin—liver cancer	7.9e-05	0.00116	CcSEcCtD
Methotrexate—Ataxia—Doxorubicin—liver cancer	7.84e-05	0.00115	CcSEcCtD
Methotrexate—Asthma—Epirubicin—liver cancer	7.79e-05	0.00115	CcSEcCtD
Methotrexate—Eosinophilia—Epirubicin—liver cancer	7.71e-05	0.00114	CcSEcCtD
Methotrexate—Liver function test abnormal—Doxorubicin—liver cancer	7.7e-05	0.00113	CcSEcCtD
Methotrexate—Pancreatitis—Epirubicin—liver cancer	7.63e-05	0.00112	CcSEcCtD
Methotrexate—Vomiting—Sorafenib—liver cancer	7.62e-05	0.00112	CcSEcCtD
Methotrexate—Rash—Sorafenib—liver cancer	7.55e-05	0.00111	CcSEcCtD
Methotrexate—Dermatitis—Sorafenib—liver cancer	7.55e-05	0.00111	CcSEcCtD
Methotrexate—Breast disorder—Doxorubicin—liver cancer	7.53e-05	0.00111	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—liver cancer	7.51e-05	0.00111	CcSEcCtD
Methotrexate—Headache—Sorafenib—liver cancer	7.51e-05	0.00111	CcSEcCtD
Methotrexate—Pancytopenia—Epirubicin—liver cancer	7.39e-05	0.00109	CcSEcCtD
Methotrexate—Dysuria—Epirubicin—liver cancer	7.28e-05	0.00107	CcSEcCtD
Methotrexate—Neutropenia—Epirubicin—liver cancer	7.28e-05	0.00107	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Epirubicin—liver cancer	7.24e-05	0.00107	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—liver cancer	7.2e-05	0.00106	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—liver cancer	7.13e-05	0.00105	CcSEcCtD
Methotrexate—Nausea—Sorafenib—liver cancer	7.12e-05	0.00105	CcSEcCtD
Methotrexate—Photosensitivity reaction—Epirubicin—liver cancer	7.11e-05	0.00105	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—liver cancer	7.06e-05	0.00104	CcSEcCtD
Methotrexate—Pneumonia—Epirubicin—liver cancer	6.98e-05	0.00103	CcSEcCtD
Methotrexate—Infestation—Epirubicin—liver cancer	6.94e-05	0.00102	CcSEcCtD
Methotrexate—Drowsiness—Epirubicin—liver cancer	6.94e-05	0.00102	CcSEcCtD
Methotrexate—Infestation NOS—Epirubicin—liver cancer	6.94e-05	0.00102	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Epirubicin—liver cancer	6.88e-05	0.00101	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—liver cancer	6.84e-05	0.00101	CcSEcCtD
Methotrexate—Renal failure—Epirubicin—liver cancer	6.82e-05	0.00101	CcSEcCtD
Methotrexate—Stomatitis—Epirubicin—liver cancer	6.77e-05	0.000997	CcSEcCtD
Methotrexate—Conjunctivitis—Epirubicin—liver cancer	6.75e-05	0.000994	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—liver cancer	6.74e-05	0.000992	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—liver cancer	6.74e-05	0.000992	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Doxorubicin—liver cancer	6.7e-05	0.000986	CcSEcCtD
Methotrexate—Sweating—Epirubicin—liver cancer	6.66e-05	0.00098	CcSEcCtD
Methotrexate—Haematuria—Epirubicin—liver cancer	6.62e-05	0.000975	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—liver cancer	6.58e-05	0.000969	CcSEcCtD
Methotrexate—Hepatobiliary disease—Epirubicin—liver cancer	6.57e-05	0.000967	CcSEcCtD
Methotrexate—Epistaxis—Epirubicin—liver cancer	6.55e-05	0.000965	CcSEcCtD
Methotrexate—Agranulocytosis—Epirubicin—liver cancer	6.48e-05	0.000954	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—liver cancer	6.46e-05	0.000952	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—liver cancer	6.42e-05	0.000946	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—liver cancer	6.42e-05	0.000946	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—liver cancer	6.42e-05	0.000946	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—liver cancer	6.37e-05	0.000938	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—liver cancer	6.31e-05	0.00093	CcSEcCtD
Methotrexate—ABCB1—liver—liver cancer	6.28e-05	0.00206	CbGeAlD
Methotrexate—Haemoglobin—Epirubicin—liver cancer	6.26e-05	0.000923	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—liver cancer	6.26e-05	0.000922	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—liver cancer	6.24e-05	0.00092	CcSEcCtD
Methotrexate—Hepatitis—Epirubicin—liver cancer	6.23e-05	0.000918	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—liver cancer	6.23e-05	0.000918	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—liver cancer	6.19e-05	0.000911	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—liver cancer	6.16e-05	0.000907	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—liver cancer	6.15e-05	0.000907	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—liver cancer	6.12e-05	0.000902	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—liver cancer	6.11e-05	0.0009	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—liver cancer	6.08e-05	0.000895	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—liver cancer	6.06e-05	0.000892	CcSEcCtD
Methotrexate—Visual impairment—Epirubicin—liver cancer	6.01e-05	0.000885	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—liver cancer	5.99e-05	0.000883	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—liver cancer	5.89e-05	0.000868	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—liver cancer	5.82e-05	0.000858	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—liver cancer	5.81e-05	0.000856	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—liver cancer	5.8e-05	0.000854	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—liver cancer	5.78e-05	0.000852	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—liver cancer	5.77e-05	0.000849	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—liver cancer	5.77e-05	0.000849	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—liver cancer	5.72e-05	0.000843	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—liver cancer	5.7e-05	0.000839	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—liver cancer	5.65e-05	0.000833	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—liver cancer	5.65e-05	0.000833	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—liver cancer	5.63e-05	0.000829	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—liver cancer	5.62e-05	0.000827	CcSEcCtD
Methotrexate—Chills—Epirubicin—liver cancer	5.59e-05	0.000824	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—liver cancer	5.56e-05	0.000819	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—liver cancer	5.51e-05	0.000811	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—liver cancer	5.46e-05	0.000804	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—liver cancer	5.45e-05	0.000803	CcSEcCtD
Methotrexate—Erythema—Epirubicin—liver cancer	5.43e-05	0.000799	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—liver cancer	5.43e-05	0.000799	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—liver cancer	5.39e-05	0.000794	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—liver cancer	5.38e-05	0.000792	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—liver cancer	5.35e-05	0.000788	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—liver cancer	5.31e-05	0.000783	CcSEcCtD
Methotrexate—Back pain—Epirubicin—liver cancer	5.25e-05	0.000773	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—liver cancer	5.23e-05	0.000771	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—liver cancer	5.21e-05	0.000767	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—liver cancer	5.2e-05	0.000766	CcSEcCtD
Methotrexate—Chills—Doxorubicin—liver cancer	5.17e-05	0.000762	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—liver cancer	5.11e-05	0.000753	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—liver cancer	5.1e-05	0.000751	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—liver cancer	5.05e-05	0.000744	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—liver cancer	5.03e-05	0.000741	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—liver cancer	5.02e-05	0.000739	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—liver cancer	5.02e-05	0.000739	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—liver cancer	5.01e-05	0.000739	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—liver cancer	4.92e-05	0.000724	CcSEcCtD
Methotrexate—Malaise—Epirubicin—liver cancer	4.89e-05	0.000721	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—liver cancer	4.87e-05	0.000718	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—liver cancer	4.86e-05	0.000715	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—liver cancer	4.86e-05	0.000715	CcSEcCtD
Methotrexate—Cough—Epirubicin—liver cancer	4.73e-05	0.000697	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—liver cancer	4.73e-05	0.000697	CcSEcCtD
Methotrexate—Convulsion—Epirubicin—liver cancer	4.7e-05	0.000692	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—liver cancer	4.66e-05	0.000686	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—liver cancer	4.64e-05	0.000683	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—liver cancer	4.62e-05	0.00068	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—liver cancer	4.62e-05	0.00068	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—liver cancer	4.62e-05	0.00068	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	4.59e-05	0.000676	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—liver cancer	4.56e-05	0.000672	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—liver cancer	4.53e-05	0.000667	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—liver cancer	4.51e-05	0.000664	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—liver cancer	4.49e-05	0.000662	CcSEcCtD
Methotrexate—Confusional state—Epirubicin—liver cancer	4.46e-05	0.000658	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—liver cancer	4.43e-05	0.000652	CcSEcCtD
Methotrexate—Infection—Epirubicin—liver cancer	4.4e-05	0.000648	CcSEcCtD
Methotrexate—Cough—Doxorubicin—liver cancer	4.38e-05	0.000645	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—liver cancer	4.35e-05	0.000641	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—liver cancer	4.34e-05	0.00064	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—liver cancer	4.34e-05	0.000639	CcSEcCtD
Methotrexate—Skin disorder—Epirubicin—liver cancer	4.3e-05	0.000634	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—liver cancer	4.28e-05	0.000631	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—liver cancer	4.27e-05	0.00063	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—liver cancer	4.27e-05	0.00063	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—liver cancer	4.27e-05	0.00063	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	4.24e-05	0.000625	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—liver cancer	4.22e-05	0.000622	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—liver cancer	4.22e-05	0.000622	CcSEcCtD
Methotrexate—Hypotension—Epirubicin—liver cancer	4.14e-05	0.000609	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—liver cancer	4.13e-05	0.000608	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—liver cancer	4.1e-05	0.000603	CcSEcCtD
Methotrexate—Infection—Doxorubicin—liver cancer	4.07e-05	0.0006	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—liver cancer	4.03e-05	0.000594	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—liver cancer	4.02e-05	0.000592	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—liver cancer	4.01e-05	0.000591	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—liver cancer	4e-05	0.00059	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—liver cancer	3.98e-05	0.000586	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—liver cancer	3.98e-05	0.000586	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—liver cancer	3.96e-05	0.000583	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—liver cancer	3.95e-05	0.000581	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—liver cancer	3.94e-05	0.00058	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—liver cancer	3.91e-05	0.000575	CcSEcCtD
Methotrexate—Dyspepsia—Epirubicin—liver cancer	3.9e-05	0.000574	CcSEcCtD
Methotrexate—Decreased appetite—Epirubicin—liver cancer	3.85e-05	0.000567	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—liver cancer	3.83e-05	0.000564	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—liver cancer	3.82e-05	0.000563	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—liver cancer	3.82e-05	0.000562	CcSEcCtD
Methotrexate—Pain—Epirubicin—liver cancer	3.79e-05	0.000558	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—liver cancer	3.73e-05	0.00055	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—liver cancer	3.71e-05	0.000546	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—liver cancer	3.68e-05	0.000542	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—liver cancer	3.65e-05	0.000538	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—liver cancer	3.65e-05	0.000537	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—liver cancer	3.64e-05	0.000536	CcSEcCtD
Methotrexate—Gastrointestinal pain—Epirubicin—liver cancer	3.62e-05	0.000533	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—liver cancer	3.61e-05	0.000531	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—liver cancer	3.56e-05	0.000525	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—liver cancer	3.54e-05	0.000521	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—liver cancer	3.53e-05	0.00052	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—liver cancer	3.52e-05	0.000518	CcSEcCtD
Methotrexate—Pain—Doxorubicin—liver cancer	3.5e-05	0.000516	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—liver cancer	3.5e-05	0.000516	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—liver cancer	3.5e-05	0.000516	CcSEcCtD
Methotrexate—Feeling abnormal—Doxorubicin—liver cancer	3.38e-05	0.000497	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—liver cancer	3.35e-05	0.000493	CcSEcCtD
Methotrexate—Hypersensitivity—Epirubicin—liver cancer	3.26e-05	0.000481	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—liver cancer	3.25e-05	0.000479	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—liver cancer	3.24e-05	0.000477	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—liver cancer	3.24e-05	0.000477	CcSEcCtD
Methotrexate—Asthenia—Epirubicin—liver cancer	3.18e-05	0.000468	CcSEcCtD
Methotrexate—Pruritus—Epirubicin—liver cancer	3.13e-05	0.000461	CcSEcCtD
Methotrexate—Diarrhoea—Epirubicin—liver cancer	3.03e-05	0.000446	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—liver cancer	3.02e-05	0.000445	CcSEcCtD
Methotrexate—Asthenia—Doxorubicin—liver cancer	2.94e-05	0.000433	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—liver cancer	2.93e-05	0.000431	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—liver cancer	2.9e-05	0.000427	CcSEcCtD
Methotrexate—Vomiting—Epirubicin—liver cancer	2.82e-05	0.000415	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—liver cancer	2.8e-05	0.000413	CcSEcCtD
Methotrexate—Rash—Epirubicin—liver cancer	2.79e-05	0.000411	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—liver cancer	2.79e-05	0.000411	CcSEcCtD
Methotrexate—Headache—Epirubicin—liver cancer	2.77e-05	0.000409	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—liver cancer	2.71e-05	0.000399	CcSEcCtD
Methotrexate—Nausea—Epirubicin—liver cancer	2.63e-05	0.000387	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—liver cancer	2.6e-05	0.000384	CcSEcCtD
Methotrexate—Rash—Doxorubicin—liver cancer	2.58e-05	0.000381	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—liver cancer	2.58e-05	0.00038	CcSEcCtD
Methotrexate—Headache—Doxorubicin—liver cancer	2.57e-05	0.000378	CcSEcCtD
Methotrexate—Nausea—Doxorubicin—liver cancer	2.43e-05	0.000358	CcSEcCtD
Methotrexate—SLCO1B1—Metabolism—GOT1—liver cancer	3.83e-06	6.47e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GGT1—liver cancer	3.83e-06	6.47e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CG—liver cancer	3.81e-06	6.44e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PIK3CA—liver cancer	3.81e-06	6.43e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—CDKN1A—liver cancer	3.81e-06	6.42e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ALB—liver cancer	3.79e-06	6.4e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	3.78e-06	6.39e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTA3—liver cancer	3.77e-06	6.37e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CB—liver cancer	3.77e-06	6.36e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—MTHFR—liver cancer	3.76e-06	6.34e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—CDKN1B—liver cancer	3.75e-06	6.33e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—liver cancer	3.75e-06	6.32e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—KRAS—liver cancer	3.72e-06	6.28e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—liver cancer	3.71e-06	6.27e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTA1—liver cancer	3.7e-06	6.25e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GSTM1—liver cancer	3.7e-06	6.25e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PPARA—liver cancer	3.69e-06	6.22e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—IL6—liver cancer	3.68e-06	6.21e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CB—liver cancer	3.68e-06	6.21e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PPARG—liver cancer	3.68e-06	6.21e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.67e-06	6.19e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NAT2—liver cancer	3.66e-06	6.18e-05	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—RAF1—liver cancer	3.65e-06	6.15e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	3.63e-06	6.13e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GSTP1—liver cancer	3.62e-06	6.12e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYCS—liver cancer	3.62e-06	6.11e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—HMOX1—liver cancer	3.57e-06	6.03e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MAPK14—liver cancer	3.57e-06	6.03e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GGT1—liver cancer	3.55e-06	5.99e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GOT1—liver cancer	3.55e-06	5.99e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—CTNNB1—liver cancer	3.55e-06	5.98e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—TGFB1—liver cancer	3.53e-06	5.95e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.52e-06	5.94e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTHFR—liver cancer	3.52e-06	5.93e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ALDOB—liver cancer	3.51e-06	5.92e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP1A1—liver cancer	3.51e-06	5.92e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TERT—liver cancer	3.51e-06	5.92e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CD—liver cancer	3.5e-06	5.91e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CG—liver cancer	3.5e-06	5.9e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PIK3CA—liver cancer	3.48e-06	5.88e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	3.48e-06	5.88e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—STAT3—liver cancer	3.48e-06	5.87e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	3.47e-06	5.86e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—CDKN1A—liver cancer	3.46e-06	5.84e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—F2—liver cancer	3.46e-06	5.84e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ALB—liver cancer	3.45e-06	5.83e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTA4—liver cancer	3.45e-06	5.82e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTP1—liver cancer	3.44e-06	5.81e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PIK3CA—liver cancer	3.42e-06	5.77e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—HMOX1—liver cancer	3.4e-06	5.73e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—liver cancer	3.4e-06	5.73e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—STAT3—liver cancer	3.4e-06	5.73e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PPARG—liver cancer	3.38e-06	5.7e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTA2—liver cancer	3.36e-06	5.68e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CD—liver cancer	3.35e-06	5.66e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CRABP1—liver cancer	3.35e-06	5.65e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CB—liver cancer	3.35e-06	5.65e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—PPARA—liver cancer	3.35e-06	5.65e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GSTM1—liver cancer	3.33e-06	5.62e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CG—liver cancer	3.31e-06	5.59e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.31e-06	5.59e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ALB—liver cancer	3.31e-06	5.58e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—liver cancer	3.31e-06	5.58e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—MTHFR—liver cancer	3.27e-06	5.52e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTA1—liver cancer	3.24e-06	5.48e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	3.24e-06	5.47e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—liver cancer	3.23e-06	5.45e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TGFB1—liver cancer	3.22e-06	5.44e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	3.22e-06	5.43e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPARA—liver cancer	3.21e-06	5.42e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NAT2—liver cancer	3.21e-06	5.41e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTP1—liver cancer	3.19e-06	5.38e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTM1—liver cancer	3.17e-06	5.34e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—liver cancer	3.16e-06	5.34e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP1A1—liver cancer	3.16e-06	5.33e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CG—liver cancer	3.16e-06	5.33e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—liver cancer	3.16e-06	5.33e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFB1—liver cancer	3.15e-06	5.31e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—HMOX1—liver cancer	3.15e-06	5.31e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—liver cancer	3.11e-06	5.25e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—liver cancer	3.09e-06	5.21e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALDOB—liver cancer	3.08e-06	5.19e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CD—liver cancer	3.08e-06	5.19e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CB—liver cancer	3.05e-06	5.15e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PPARG—liver cancer	3.05e-06	5.14e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ALB—liver cancer	3.04e-06	5.12e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	3.02e-06	5.09e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	3e-06	5.07e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP1A1—liver cancer	3e-06	5.06e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—liver cancer	2.99e-06	5.04e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	2.96e-06	4.99e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APC—liver cancer	2.95e-06	4.98e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—MTHFR—liver cancer	2.94e-06	4.97e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CRABP1—liver cancer	2.93e-06	4.95e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	2.93e-06	4.95e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTM1—liver cancer	2.93e-06	4.95e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HPGDS—liver cancer	2.93e-06	4.94e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CB—liver cancer	2.92e-06	4.93e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—liver cancer	2.92e-06	4.92e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CD—liver cancer	2.91e-06	4.91e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.91e-06	4.91e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARA—liver cancer	2.89e-06	4.87e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.88e-06	4.87e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SERPINE1—liver cancer	2.88e-06	4.86e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—liver cancer	2.87e-06	4.85e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—liver cancer	2.86e-06	4.83e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	2.86e-06	4.83e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—liver cancer	2.84e-06	4.8e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MTHFR—liver cancer	2.8e-06	4.72e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—liver cancer	2.79e-06	4.71e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP1A1—liver cancer	2.78e-06	4.69e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BRAF—liver cancer	2.78e-06	4.68e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CD—liver cancer	2.77e-06	4.68e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CG—liver cancer	2.75e-06	4.64e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARA—liver cancer	2.74e-06	4.63e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—liver cancer	2.74e-06	4.63e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ALB—liver cancer	2.74e-06	4.62e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CB—liver cancer	2.68e-06	4.52e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—liver cancer	2.68e-06	4.52e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—liver cancer	2.65e-06	4.48e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPARG—liver cancer	2.65e-06	4.48e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.65e-06	4.47e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PSMD10—liver cancer	2.61e-06	4.4e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PSMA4—liver cancer	2.61e-06	4.4e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—RAF1—liver cancer	2.6e-06	4.39e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CD—liver cancer	2.6e-06	4.38e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.59e-06	4.38e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MTHFR—liver cancer	2.59e-06	4.37e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SERPINE1—liver cancer	2.57e-06	4.33e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HPGDS—liver cancer	2.57e-06	4.33e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARA—liver cancer	2.54e-06	4.29e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GOT2—liver cancer	2.54e-06	4.28e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CB—liver cancer	2.54e-06	4.28e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—liver cancer	2.54e-06	4.28e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—liver cancer	2.48e-06	4.18e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CG—liver cancer	2.47e-06	4.17e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.47e-06	4.16e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	2.45e-06	4.14e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—liver cancer	2.44e-06	4.11e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—liver cancer	2.43e-06	4.1e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CB—liver cancer	2.42e-06	4.08e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CD—liver cancer	2.42e-06	4.08e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	2.41e-06	4.07e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARG—liver cancer	2.39e-06	4.03e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2E1—liver cancer	2.39e-06	4.03e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ALB—liver cancer	2.39e-06	4.03e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—liver cancer	2.37e-06	4e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CG—liver cancer	2.35e-06	3.97e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—liver cancer	2.33e-06	3.93e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RAF1—liver cancer	2.32e-06	3.91e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.31e-06	3.9e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—liver cancer	2.3e-06	3.88e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PSMA4—liver cancer	2.29e-06	3.86e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PSMD10—liver cancer	2.29e-06	3.86e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARG—liver cancer	2.27e-06	3.83e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CB—liver cancer	2.26e-06	3.82e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTOR—liver cancer	2.26e-06	3.82e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—liver cancer	2.26e-06	3.81e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	2.25e-06	3.8e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—liver cancer	2.24e-06	3.79e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—liver cancer	2.24e-06	3.78e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYCS—liver cancer	2.23e-06	3.77e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GOT2—liver cancer	2.22e-06	3.75e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GGT1—liver cancer	2.19e-06	3.7e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GOT1—liver cancer	2.19e-06	3.7e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—liver cancer	2.19e-06	3.69e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	2.18e-06	3.68e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CG—liver cancer	2.18e-06	3.67e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CD—liver cancer	2.17e-06	3.67e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—liver cancer	2.16e-06	3.64e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ALB—liver cancer	2.15e-06	3.62e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1B—liver cancer	2.12e-06	3.58e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CB—liver cancer	2.11e-06	3.55e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARG—liver cancer	2.1e-06	3.54e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2E1—liver cancer	2.09e-06	3.53e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CD—liver cancer	2.07e-06	3.49e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—liver cancer	2.04e-06	3.45e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ALB—liver cancer	2.04e-06	3.44e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—liver cancer	2.01e-06	3.39e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—liver cancer	1.99e-06	3.36e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—liver cancer	1.98e-06	3.34e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.97e-06	3.33e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTP1—liver cancer	1.97e-06	3.32e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1A—liver cancer	1.96e-06	3.31e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYCS—liver cancer	1.96e-06	3.3e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HMOX1—liver cancer	1.94e-06	3.28e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GOT1—liver cancer	1.92e-06	3.24e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GGT1—liver cancer	1.92e-06	3.24e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CD—liver cancer	1.91e-06	3.23e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CB—liver cancer	1.9e-06	3.2e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ALB—liver cancer	1.89e-06	3.19e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—liver cancer	1.88e-06	3.17e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—liver cancer	1.86e-06	3.14e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—liver cancer	1.83e-06	3.09e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—liver cancer	1.82e-06	3.07e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTM1—liver cancer	1.81e-06	3.05e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CB—liver cancer	1.8e-06	3.04e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—liver cancer	1.78e-06	3.01e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—liver cancer	1.75e-06	2.95e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTP1—liver cancer	1.72e-06	2.91e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1A1—liver cancer	1.71e-06	2.89e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HMOX1—liver cancer	1.7e-06	2.87e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—liver cancer	1.68e-06	2.84e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—liver cancer	1.67e-06	2.81e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CB—liver cancer	1.67e-06	2.81e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—liver cancer	1.63e-06	2.76e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—liver cancer	1.63e-06	2.74e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—liver cancer	1.62e-06	2.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTHFR—liver cancer	1.6e-06	2.7e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTM1—liver cancer	1.58e-06	2.67e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARA—liver cancer	1.57e-06	2.65e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—liver cancer	1.55e-06	2.61e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—liver cancer	1.52e-06	2.56e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1A1—liver cancer	1.5e-06	2.54e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—liver cancer	1.5e-06	2.53e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—liver cancer	1.5e-06	2.53e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—liver cancer	1.47e-06	2.49e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—liver cancer	1.46e-06	2.46e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—liver cancer	1.43e-06	2.42e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.41e-06	2.38e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTHFR—liver cancer	1.4e-06	2.36e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—liver cancer	1.38e-06	2.33e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARA—liver cancer	1.37e-06	2.32e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CG—liver cancer	1.34e-06	2.27e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—liver cancer	1.33e-06	2.25e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARG—liver cancer	1.3e-06	2.19e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—liver cancer	1.28e-06	2.17e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—liver cancer	1.28e-06	2.15e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—liver cancer	1.26e-06	2.13e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—liver cancer	1.22e-06	2.06e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—liver cancer	1.2e-06	2.03e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CD—liver cancer	1.18e-06	1.99e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CG—liver cancer	1.18e-06	1.99e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—liver cancer	1.16e-06	1.95e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARG—liver cancer	1.14e-06	1.92e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—liver cancer	1.13e-06	1.9e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—liver cancer	1.1e-06	1.85e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—liver cancer	1.05e-06	1.77e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CD—liver cancer	1.03e-06	1.75e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CB—liver cancer	1.03e-06	1.74e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALB—liver cancer	1.02e-06	1.72e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—liver cancer	1.02e-06	1.72e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—liver cancer	9.44e-07	1.59e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CB—liver cancer	9.02e-07	1.52e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—liver cancer	8.97e-07	1.51e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—liver cancer	8.3e-07	1.4e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—liver cancer	6.27e-07	1.06e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—liver cancer	5.5e-07	9.28e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—liver cancer	5.12e-07	8.65e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—liver cancer	4.49e-07	7.58e-06	CbGpPWpGaD
